tbuckley/cabot-search huggingface dataset:
Accelerated concomitant boost conformal radiotherapy versus conventional sequential boost in patients with locally advanced inoperable non-small cell lung cancer.
Authors: Salah Eldeen Elmesidy, Mohamad M Moussa, Dalia O Darwish, Heba A Khafagy, Eman Amin, Maha Kamal
Journal: Journal of Clinical Oncology (2015)

e18530 Background: Management of advanced non-small cell lung cancer is rapidly evolving. Advances in combined chemoradiation therapy led to improvements in patient survival, but most patients relapse, making it necessary for exploration of new radiation schedules aiming at better local control & survival. Methods: Study was performed in Clinical Oncology Dep, Faculty of Medicine, Cairo University between January 2010 and January 2012. 50 patients stage III inoperable newly diagnosed Stage IIIA & IIIB NSCLC histologically or cytologically proven (AJCC sixth edition), ≥ 18 years; ≤ 70, Karnofsky performance (KPS) > 70, No prior treatment, Normal kidney & liver functions, No distant metastases, No severe heart or pulmonary disease. Patients were recruited &randomized after 2 cycles of induction chemotherapy (gemcitabine-carboplatin) into 2 groups; 25 treated by a concomitant boost & 25 by sequential boost using 3D conformal beams to a total dose 64.2 Gy Group(A) received 52.2 Gy /29f/6w with concomitant boost 12 Gy/8f (at least 6 hours between 2 sessions) given during first 2 weeks, Group(B) conventional fractionation with sequential boost over 8 weeks. Primary end point was progression free survival, secondary end points response rate & toxicity. Results: Both groups were well balanced. Target coverage was adequate in both groups (p = 0.246). No statistically significant difference between 2 groups regarding doses to OAR. The 2 groups were comparable regarding cardiac, pulmonary, esophageal toxicity with grade II esophagitis in 54% of patients. After a median follow-up 26 months, progression-free survival: 19 months in sequential arm versus 20 months in concomitant arm (P = 0.275). Response Rate was 84% in concomitant arm and 80% in conventional arm with no statistical significant difference (P = 1 ). Median survival in concomitant arm ranged from 23-28 months & sequential arm 17-24 months. Conclusions: Concomitant boost is not inferior to sequential boost for locally advanced inoperable NSCLC regarding acute toxicity, response rate and PFS. It can be used to reduce number of treatment fractions without increasing toxicity or having less tumor control outcome
Impact of BMI on survival and toxicity in early breast cancer: An exploratory analysis of prospective randomized phase III study N-SAS BC02 and 03.
Authors: Yoichi Naito, Yasuo Ohashi, Isao Yokota, Toru Watanabe, Hiroji Iwata, Shozo Ohsumi, Shinji Ohno, Yasuo Hozumi, Seiichiro Yamamoto, Masato Takahashi, Tomohiko Aihara, Hirofumi Mukai
Journal: Journal of Clinical Oncology (2015)

11102 Background: Obesity is reported to be associated with worse prognosis in early breast cancer. As obesity is rare and low BMI is relatively common in Japanese population compared to Caucasians, the impact of BMI on survival and toxicity in Japanese cohort should be assessed. Here we report an exploratory analysis of the data included in randomized phase III trials for early breast cancer in Japan. Methods: Patients included in phase III trial N-SAS BC02 or BC03 were analyzed. N-SAS BC02 investigated four arms of adjuvant chemotherapy consisted of taxane alone or in combination with anthracycline-containing regimen (median follow up of 6.1 years). NSAS BC03 compared anastorozole with tamoxifen as adjuvant endocrine therapy (median follow up of 6.4 years). The correlations of BMI and overall survival or toxicity were retrospectively analyzed. Results: A total of 1726 patients were included in our study. Median age was 56 years, 71.2% of tumors were ER positive, and 9.7% were HER2 overexpressed, 76% had lymph node metastasis. Mean value of BMI was 23.3 and only 4.6% of patients had BMI over 30. 33.1% of patients had BMI under 22 and 4.8% had BMI under 18.5. In the Cox proportional hazards model adjusted randomized arms, lower BMI was significantly associated with worse prognosis (BMI > = 27 vs < 27, HR 0.55, p = 0.025). The same trend was observed in adjusted analysis for prognostic factors (HR 0.61, p = 0.064). Subgroup analysis of hormone receptor positive cohort showed that higher BMI was correlated with worse prognosis in premenopausal patients; on the other hand, in postmenopausal patients higher BMI was correlated with better prognosis. There was no significant correlation between BMI and toxicity. Conclusions: We confirmed that obesity was rare in Japanese patients with early breast cancer. In this non-obese population, lower BMI was correlated with worse prognosis without significant impact on toxicity. Subgroup analysis suggested interaction between menopausal status and BMI on survival. Detrimental effect of higher BMI on survival is limited to premenopausal hormone receptor positive patients.
Strain- and Species-Level Variation in the Microbiome of Diabetic Wounds Is Associated with Clinical Outcomes and Therapeutic Efficacy
Authors: Lindsay R. Kalan, Jacquelyn S. Meisel, Michael A. Loesche, Joseph Horwinski, Ioana Soaita, Xiaoxuan Chen, Aayushi Uberoi, Sue E. Gardner, Elizabeth A. Grice
Journal: Cell Host & Microbe (2019)
FRI-477-Factors associated with good postprogression survival in post-sorafenib progressed advanced hepatocellular carcinoma pateitns not eligible for regorafenib
Authors: Chang Wook Kim, Hee Yeon Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Pil Soo Sung, Jeong Won Jang, Hee Chul Nam, Jong Young Choi, Si Hyun Bae, Seung Kew Yoon
Journal: Journal of Hepatology (2019)
Langerhans cell histiocytosis in children: Correlation of <i>BRAF</i> status with clinical characteristic.
Authors: Sébastien Héritier, Jean-François Emile, Mohamed Barkaoui, Anne Moreau, Valerie Rigau, Frédérique Dijoud, Catherine Chassagne, Frédéric Charlotte, Karima Mokhtari, Sabah Boudjemaa, Aurore Coulomb, Michel Peuchmaur, Marie-Christine Copin, Sylvie Fraitag, Thierry Molina, Eric Jeziorski, Caroline Thomas, Mathilde de Menthon, Julien Haroche, Jean Donadieu
Journal: Journal of Clinical Oncology (2015)

10003 Background: In 2010, BRAF mutations were reported in patients with Langerhans cell histiocytosis (LCH). We have shown that BRAFV600E mutations are also present in more than half of Erdheim Chester disease (EDC), and that lesions of both ECD and LCH are responsive to treatment with vemurafenib. This study aims to define the clinical features of LCH children with or without BRAF mutations. Methods: 319 children (age < 18 years) were included in the French nationwide GeneHistio study. This study was approved by an ethical comity, and signed informed consent was obtained for all patients. LCH diagnosis was validated by pathological central review, and detection of BRAFV600Emutation was performed by pyrosequencing. Results: 240 (80%) patients were informative for BRAF mutation. This cohort was similar to the 1423 patients of the French LCH cohort who were not analyzed for BRAF, except for the frequency of hematologic involvement (15% versus 10%, P = 0.044). Median age at diagnosis was 5.0 years [range, 0-17 yr], mean follow-up was 4.7 years, and sex ratio was 1.2. LCH was a single-system disease (SS) in 55%, and multisystemic disease without (MSRO-) or with (MSRO+) risk organ in 20% and 25% of cases respectively. Affected organs were bone (82%), skin (33%), pituitary (17%), hematological involvement (15%), liver (14%), spleen (13%), lung (13%) and central nervous system (CNS) (7%). The 5 years relapse free survival was 58%, and 7 death occurred. BRAFV600E mutation was detected in 125 cases (52%). Univariate analysis showed that BRAFV600E was associated with skin or liver or spleen involvement, or with hematological dysfunction (P < 0.05). Furthermore the frequency of BRAFV600E was different in children with SS, MSRO- and MSRO+ disease (P < 0.005). Multivariate analysis showed that skin and hematologic involvement had a higher frequency of BRAFV600E with Odds ratio of 3.6 (95%CI [1.6-8.5] and 8.3 (95%CI [1.7-39.9] respectively. Sequelae of LCH were detected in 24% and 12% of patients with or without BRAFV600E (P = 0.02). Conclusions: In children with LCH, BRAFV600E mutation is associated with features commonly found in more aggressive forms of the disease.
SAT-478-Comparison of prediction models for hepatocellular carcinoma development in treatment naive chronic hepatitis B patients with cirrhosis
Authors: Hyunwoo Oh, Hyo Young Lee, Dae Won Jun, Sang Bong Ahn, Jaeyoon Jeong, Eileen L Yoon, Hyoung Su Kim, Jae-Jun Shim, Yong Kyun Cho, Soung Won Jeong, Sung Eun Kim
Journal: Journal of Hepatology (2019)
FRI-297-Trans-signaling blockade induces mature-onset obesity and insulin resistance in mice via suppression of PPARalpha
Authors: tali lanton, Orr Levkovitch, Rinat Abramovitch, Sharon Perles, Joseph Tam, Shiran Udi, Evan Williams, Ruedi Aebersold, Eran Elinav, Meirav Pevsner-Fischer, Jacob Rachmilewitz, Stefan Rose-John, Eithan Galun, Jonathan Axelrod
Journal: Journal of Hepatology (2019)
Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn’s Disease
Authors: Martinus A. Cozijnsen, Assaf Ben Shoham, Ben Kang, Byung-Ho Choe, Yon Ho Choe, Maria M.E. Jongsma, Richard K. Russell, Frank M. Ruemmele, Johanna C. Escher, Lissy de Ridder, Sibylle Koletzko, Javier Martín-de-Carpi, Jeffrey Hyams, Thomas Walters, Anne Griffiths, Dan Turner
Journal: Clinical Gastroenterology and Hepatology (2019)
TCTAP C-046 Acute Total Left Main Stem Occlusion with Cardiogenic Shock After Cardiac Arrest with Return of Spontaneous Circulation: Successful Percutaneous Revascularization Without Mechanical Hemodynamic Support
Authors: San Samrany, Nhem Sophearath, Chan Sokha, Sok Chour
Journal: Journal of the American College of Cardiology (2019)
Family accommodation in obsessive-compulsive disorder
Authors: L Calvocoressi, B Lewis, M Harris, S J Trufan, W K Goodman, C J McDougle, L H Price
Journal: American Journal of Psychiatry (1995)

Family accommodation of patients with obsessive-compulsive disorder, i.e., participation in symptoms and modification of personal and family routines, was assessed in relation to family stress, functioning, and attitudes toward the patient.Primary caretakers for 34 patients with obsessive-compulsive disorder were interviewed to assess the nature and frequency of accommodating behaviors. The caretakers also completed several measures of family functioning.Of the 34 spouses or parents, 30 (88.2%) reported accommodating the patient. Family accommodation correlated with poor family functioning, rejecting attitudes toward the patient, and several types of family stress.Family accommodation of patients with obsessive-compulsive disorder was associated with global family dysfunction and stress. This study suggests that families' efforts to accommodate patients may be intended to reduce patient anxiety or anger directed at relatives.
SAT-403-Polycyclic aromatic hydrocarbons can trigger a hepatocyte release of cytotoxic extracellular vesicles
Authors: Nettie van Meteren, Martine Chevanne, Isabelle Gallais, Fabienne Gauffre, Soizic Chevance, Agnès Burel, Dominique Lagadic-Gossmann, Eric Le Ferree, Odile Sergent
Journal: Journal of Hepatology (2019)
Impacts of HDAC2 inhibition on lung cancer treatment
Authors: Y.-T. Yeh, C.-R. Wu, J.-C. Lai, C.-H. Huang, Y.-F. Wei, M.-S. Huang
Journal: Annals of Oncology (2019)

Background: Approximately 80% of lung cancer is non-small cell lung cancer (NSCLC) with a median survival time of 8 to 10 months. It is critical and urgent to find the effective interventions for patients suffering from NSCLC. Histone deacetylase 2 (HDAC2) is increasingly associated with development of several solid tumors. However, its role in lung cancer remained mostly lacking. Methods: Immunohistochemistry was used to analyze the distribution patterns of HDAC2 protein in lung cancer and the results were further statistically correlated with clinicopathological characteristics and survival rate. XTT, invasion assay, flowcytometry, immunoblotting, and immunoprecipitation were used to explore the bio-impacts and underlying mechanisms of HDAC2 and its interplay with nicotine in lung cancer cells. Results: The Kaplan–Meier plotter shows that 1926 lung cancer patients with high HDAC2 mRNA levels will have a poor overall survival rate (p = 0.004). Increased HDAC2 mRNA expression predicts an improved overall survival of non-smoker patient group (p = 0.018) but not that of smoker patient group. Further immunohistochemistry showed similar results (p < 0.001). Intriguingly, this association seen in smoker and non-smoker groups was demonstrated in only squamous cell lung cancer, providing the specific interplay between HDAC2 and carcinogenic content of cigarette. Treatment with nicotine induced the NO production through rapidly increasing NOS2 expression and HDAC2 was subsequently nitrosylated. Knockdown of HDAC2 reduced nicotine-induced NOS2 expression and invasive activity. Ectopic HDAC2 overexpression enhanced nicotine-mediated NOS2 induction. Interestingly, ectopic overexpression of Cys262/274Ala HDAC2 mutant, un-nitrosylated, inhibited the invasive activity. HDAC2 specific siRNA and inhibitor enhanced the cytotoxicity of cisplatin and abolished the cisplatin-mediated cyclin B1 induction. Conclusions: Our results implicated that HDAC2 might be required for cigarette carcinogenic content-mediated advanced development or treatment failure in lung cancer. NOS2 provides the link between nicotine and HDAC2 in lung cancer. Inhibition of HDAC2 activity may increase therapeutic effects of cisplatin-based treatments in NSCLC. Legal entity responsible for the study: Yao-Tsung Yeh. Funding: MOST, Taiwan (R.O.C). Disclosure: All authors have declared no conflicts of interest.
Common Polymorphisms In The Cd43 Gene Region Are Associated With Tuberculosis Susceptibility And Mortality
Authors: M Campo, A K Randhawa, S Dunstan, J Farrar, M Caws, N D Bang, N N Lan, Chau Tth., D J Horne, N T Thuong, G Thwaites, T R Hawn
Journal: American Journal of Respiratory and Critical Care Medicine (2014)
SAT-039-The assessment of sarcopenia by quadriceps muscle ultrasound in patients with liver cirrhosis
Authors: Stefania Gioia, Barbara Lattanzi, Stefano Ginanni Corradini, Daria D’ambrosio, Nicoletta Fabrini, Angelo Bruni, Alessandra Pigliacelli, Adriano De Santis, Manuela Merli
Journal: Journal of Hepatology (2019)
Acne and obesity: A nationwide study of 600,404 adolescents
Authors: Igor Snast, Adam Dalal, Gilad Twig, Nadav Astman, Ron Kedem, Dan Levin, Yifat Erlich, Yael Anne Leshem, Moshe Lapidoth, Emmilia Hodak, Assi Levi
Journal: Journal of the American Academy of Dermatology (2019)
Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis
Authors: Andrew McAuley, Norah E Palmateer, David J Goldberg, Kirsten M A Trayner, Samantha J Shepherd, Rory N Gunson, Rebecca Metcalfe, Catriona Milosevic, Avril Taylor, Alison Munro, Sharon J Hutchinson
Journal: The Lancet HIV (2019)
LBO-08-Growth analysis in children with progressive familial intrahepatic cholestasis treated with the apical sodium-dependent bile acid transporter inhibitor maralixibat
Authors: Richard Thompson, Deirdre Kelly, Sanjay Rajwal, Alexander Miethke, Nisreen Soufi, Christine Rivet, Irena Jankowska, Cara mack, Thomas Jaecklin, Robert Squires, Kathleen Loomes
Journal: Journal of Hepatology (2019)
TCTAP A-068 Long-term Follow-up from the NANOLUTE Registry on the Performance of Sirolimus Coated Balloon for the Treatment of In-Stent Restenosis
Authors: Bernardo Cortese, Sameer Dani, Keyur Parikh, Prathap Kumar Pillai, Ranjan Shetty, Jagdish Hiremath, Dinesh Shah
Journal: Journal of the American College of Cardiology (2019)
Platelets in cardiac ischaemia/reperfusion injury: a promising therapeutic target
Authors: Melanie Ziegler, Xiaowei Wang, Karlheinz Peter
Journal: Cardiovascular Research (2019)

Acute myocardial infarction (AMI) is the single leading cause of mortality and morbidity worldwide. A key component of AMI therapy is the timely reopening of occluded vessels to prevent further ischaemic damage to the myocardium. However, reperfusion of the ischaemic myocardium can itself trigger reperfusion injury causing up to 50% of the overall infarct size. In recent years, considerable research has been devoted to understanding the pathogenesis of ischaemia/reperfusion (I/R) injury and platelets have emerged as a major contributing factor. This review summarizes the role of platelets in the pathogenesis of I/R injury and highlights the potential of platelet-directed therapeutics to minimize cardiac I/R injury. Activated platelets infiltrate specifically into the ischaemic/reperfused myocardium and contribute to I/R injury by the formation of microthrombi, enhanced platelet-leucocyte aggregation, and the release of potent vasoconstrictor and pro-inflammatory molecules. This review demonstrates the benefits of platelet inhibition beyond their well-described anti-thrombotic effect and highlights the direct cardioprotective role of anti-platelet drugs. In particular, the inhibition of COX, the P2Y12 receptor and the GPIIb/IIIa receptor has demonstrated the potential to attenuate I/R injury. Moreover, targeting of drug candidates or regenerative cells to the activated platelets accumulated within the ischaemic/reperfused myocardium shows remarkable potential to protect the myocardium from I/R injury. Overall, activated platelets play a key role in the pathogenesis of I/R injury. Their direct inhibition as well as their use as epitopes for site-directed therapy is a unique and promising therapeutic approach for the prevention of I/R injury and ultimately the preservation of cardiac function.
Response by El Refaey et al to Letter Regarding Article, “Protein Phosphatase 2A Regulates Cardiac Na <sup>+</sup> Channels”
Authors: Mona El Refaey, Hassan Musa, Sakima A. Smith, Philip F. Binkley, Elisa Bradley, Thomas J. Hund, Peter J. Mohler
Journal: Circulation Research (2019)
Attitudes and beliefs of graduate medical trainees regarding palliative care at a comprehensive cancer center.
Authors: Angelique Wong, Akhila Sunkepally Reddy, Jimin Wu, Diane D Liu, Eduardo Bruera
Journal: Journal of Clinical Oncology (2015)

e20562 Background: Although studies have shown that palliative care (PC) training is lacking and should be integrated with oncology care, most cancer centers do not have established PC programs. At those that do, the current attitudes and beliefs of the trainees regarding palliative care are not fully known. We conducted a survey to determine perceptions of graduate medical trainees regarding PC at a comprehensive cancer center with an established palliative care program. Methods: 170 trainees who completed at least 9 months of training in medical, surgical, gynecologic, and radiation oncology fellowship and residency during the 2013 academic year completed an online questionnaire. This survey assessed their attitudes, beliefs, and understanding of PC as well as their training, experiences, and utilization of PC services. Descriptive, univariate, and multivariate analyses were performed. Results: 122/132 respondents (92%) were eligible. Medical (53/60, 88.3%), gynecologic (6/6, 100%) and radiation oncology trainees (20/20, 100%) reported a better understanding of PC as compared to surgical oncology trainees (22/36, 61.2%) (p = 0.0019). 112/122 trainees (92%) perceived PC as beneficial to patients and families. Of those surveyed, 37 (30%) perceived that PC referral decreased hope, 108 (89%) that PC can reduce healthcare costs, 78 (64%) that PC can increase survival; and 90 (74%) would consult PC for a newly diagnosed cancer patient with symptoms. 50/51 (98%) of trainees who refer to PC most or all the time showed better understanding as compared to those who referred none of the time (33%, p < 0.0001). 82 (67%) trainees believe a mandatory PC rotation is important. Trainees with previous exposure to PC rotations endorsed a better understanding of PC 96% (46/48) vs. 74% (55/74) (p = 0.0054). Conclusions: Attitudes and beliefs were significantly worse in surgical trainees as well as those who did not refer patients to PC and those who did not have a previous PC rotation. Overall, trainees perceived PC as beneficial to patients and capable of reducing costs while increasing survival, and supported PC referrals in early-stage symptomatic patients. The majority of trainees endorse a mandatory PC rotation.
Decoding Skin Involvement in Chronic Graft-vs-Host Disease
Authors: Edward W. Cowen
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
UK universities show the way in reporting clinical trial results
Authors: Lynn Eaton
Journal: BMJ (2019)

UK universities are leading the way in reporting their clinical trial results—beating other European institutions hands down—but only after government pressure to improve, a recent study shows.1

The encouraging results, highlighted by Till Bruckner of the campaigning organisation TranspariMED, are based on data from the Evidence Based Medicine Data Lab, led by Ben Goldacre at the University of Oxford.

The latest data, outlined in a blog post,1 showed that the top five universities for reporting their results were Dundee (97% of trials), Nottingham (96%), Queen Mary University of London (94%), Oxford (93%), and King’s College, London (93%).

By comparison, reporting rates at universities outside the UK were very low, said Bruckner, TranspariMED’s founder. Copenhagen reported only 8% of its trial results, …